"Designing Growth Strategies is in our DNA"
The global rheumatoid arthritis therapeutics market size stood at USD 23,822.5 Million in 2017 and is projected to reach USD 33,958.4 Million by 2025, exhibiting a CAGR of 4.6% in the forecast period (2018-2025).
The increasing prevalence of rheumatoid arthritis globally, the launch of novel therapeutic agents, and favorable reimbursement policies for high-cost treatment products are some of the factors that are driving the growth of global rheumatoid arthritis therapeutics market. Improvements in diagnostics and healthcare infrastructure in developing countries are expected to witness an increased number of diagnosed cases.
This factor is anticipated to enable the rheumatoid arthritis therapeutics market growth during the forecast period. The growing geriatric population and rising awareness about arthritis and its prevention among patients and healthcare professionals are also expected to drive the global market during 2018-2015.
Request a Free sample to learn more about this report.
"Increasing efficiency of the drugs in the treatment of rheumatoid arthritis, combined with the favorable reimbursement policies is driving the growth of the global market"
The presence of high cost drugs and favorable reimbursement policies are the most prominent driving factors for the growth of the global rheumatoid arthritis therapeutics market. The biologics segment is estimated to have the largest market share among product types. The biologics segment accounted for a significant market share in 2017. Among product types, it is expected to be the fastest growing product segment globally. Increase in prevalence of rheumatoid arthritis in developed countries like the U.S. and other European countries is expected to boost the biologics segment during the forecast period.
To know how our report can help streamline your business, Speak to Analyst
Based on the product type, the global rheumatoid arthritis therapeutics market segments include biologics, and non-biologics. The biologics segment dominated the global rheumatoid arthritis market in 2017. Non-Biologics can be further sub-segmented into non-steroidal anti-inflammataory drugs (NSAIDs), synthetic disease-modifying antirheumatic drugs (sDMARDs), and others . Based on distribution channel, the global market segments include hospital pharmacy, retail pharmacy, and online pharmacy.
"An increasing number of patients suffering from rheumatoid arthritis in the U.S. combined with new product launches are fueling the demand for rheumatoid arthritis therapeutics in North America"
North America generated a rheumatoid arthritis therapeutics market revenue of US$ 9,929.6 Mn in 2017 and is anticipated to account for a dominant share in the global market during the forecast period. Growth witnessed in the region is driven by increasing prevalence of rheumatoid arthritis, increasing awareness about the disorder, and increasing healthcare spending. In Europe, the increasing prevalence combined with the adoption of advanced rheumatoid arthritis therapeutics is expected to drive the market growth.
Moreover, increasing penetration of rheumatoid arthritis treatment drugs, specially biologics, and increasing healthcare infrastructure in the developing countries is expected to positively impact the consumption of rheumatoid arthritis treatment products. This is anticipated to result in high growth rate of market in Asia Pacific. Latin America and Middle East & Africa account for a smaller share of the global rheumatoid arthritis therapeutics market currently, but increasing awareness and undertaking of treatment of rheumatoid arthritis is expected to drive the market growth in the future.
North America Rheumatoid Arthritis Therapeutics Market, 2017
To get more information on the regional analysis of this market, Request a Free sample
"AbbVie Inc., Pfizer Inc., Ltd., and Amgen Inc., dominated the global rheumatoid arthritis therapeutics market in 2017"
AbbVie Inc. emerged as the leading player in 2017 attributed to Humira, the mostly used medication for rheumatoid arthritis, and is expected to continue dominating the market during forecast period. The expected biosimilar erosion for Humira and sales for strong pipeline drug candidates will keep Abbvie Inc. at leading position. Top 10 market players accounted for more than 80.0% of the rheumatoid arthritis therapeutics market share. Other players operating in the rheumatoid arthritis therapeutics market are Pfizer Inc., Amgen Inc., Johnson & Johnson Services, Inc., CELGENE CORPORATION, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, UCB S.A., Eli Lilly and Company, Gilead Sciences, Inc., etc
The increasing prevalence and rising awareness about breathing disorders have resulted in demand for rheumatoid arthritis therapeutics. Additional factors expected to contribute to the growth of the market include the favorable reimbursement policies for expensive drugs in the U.S., increasing geriatric population in developed and developing countries, and increased diagnostic capabilities in developing countries. The introduction of new products in the market, along with an increasing number of patients undergoing rheumatoid arthritis treatment globally is projected to further augment the demand for rheumatoid arthritis therapeutics during the forecast period.
The report provides qualitative and quantitative insights on the rheumatoid arthritis therapeutics industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The market segments include product type, distribution channel, and geography. On the basis of product type, the market for rheumatoid arthritis therapeutics can be segmented into biologics and non-biologics.
Non-biologics can further be sub-segmented into non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drug (SDMARDs), and others. On the basis of distribution channels, the global rheumatoid arthritis therapeutics market can be segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The regions are further categorized into countries.
An Infographic Representation of Rheumatoid Arthritis Therapeutics Market
To get information on various segments, share your queries with us
Along with this, the report analysis includes market dynamics and competitive landscape. The report also offers key insights related to pipeline analysis, the regulatory scenario for key countries, pricing analysis, key industry developments, incidence & prevalence of rheumatoid arthritis, snapshot on the novel & upcoming therapies, and an overview of treatment plans for rheumatoid arthritis.
By Product Type
By Distribution Channels
As per our (Fortune Business Insights) study, the global rheumatoid arthritis therapeutics market is predicted to reach US$ 33,958.4 Million by 2025.
Increasing prevalence of rheumatoid arthritis globally, the launch of novel therapeutic agents, and favorable reimbursement policies for high-cost treatment products are some of the key factors driving the rheumatoid arthritis therapeutics market.
The biologics drug segment is the leading segment in the rheumatoid arthritis therapeutics market by product.
North America is expected to hold the highest market share in the rheumatoid arthritis therapeutics market attributed to the increasing number of patients diagnosed with rheumatoid arthritis in the U.S. combined with new product launches for the treatment of rheumatoid arthritis by the prominent players in North America.
AbbVie Inc., Pfizer Inc., Ltd., and Amgen Inc., are the top players in the rheumatoid arthritis therapeutics market.
High costs associated with the biologics, which are unaffordable by the low middle-income countries is the factor likely to hinder the rheumatoid arthritis therapeutics market growth during the forecast period.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry